



US009636400B2

(12) **United States Patent**  
**Dix et al.**(10) **Patent No.:** US 9,636,400 B2  
(45) **Date of Patent:** \*May 2, 2017(54) **VEGF SPECIFIC FUSION PROTEIN ANTAGONIST FORMULATIONS**(71) Applicant: **Regeneron Pharmaceuticals, Inc.**, Tarrytown, NY (US)(72) Inventors: **Daniel B. Dix**, LaGrangeville, NY (US); **Kelly Frye**, Mendham, NJ (US); **Susan Kautz**, Albany, NY (US)(73) Assignee: **REGENERON PHARMACEUTICALS, INC.**, Tarrytown, NY (US)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/150,840**(22) Filed: **May 10, 2016**(65) **Prior Publication Data**

US 2016/0244504 A1 Aug. 25, 2016

**Related U.S. Application Data**

(60) Continuation of application No. 14/550,385, filed on Nov. 21, 2014, now Pat. No. 9,416,167, which is a continuation of application No. 13/909,745, filed on Jun. 4, 2013, now Pat. No. 8,921,316, which is a continuation of application No. 13/428,510, filed on Mar. 23, 2012, now Pat. No. 8,710,004, which is a continuation of application No. 13/343,214, filed on Jan. 4, 2012, now Pat. No. 8,404,638, which is a division of application No. 12/835,065, filed on Jul. 13, 2010, now Pat. No. 8,110,546, which is a continuation of application No. 11/387,256, filed on Mar. 22, 2006, now abandoned.

(60) Provisional application No. 60/665,125, filed on Mar. 25, 2005.

(51) **Int. Cl.**

*A61K 39/395* (2006.01)  
*A61K 9/10* (2006.01)  
*A61K 31/4172* (2006.01)  
*A61K 31/7012* (2006.01)  
*A61K 38/18* (2006.01)  
*A61K 47/02* (2006.01)  
*A61K 47/10* (2006.01)  
*A61K 47/12* (2006.01)  
*C07K 14/71* (2006.01)  
*C07K 16/22* (2006.01)  
*A61K 9/00* (2006.01)  
*A61K 9/08* (2006.01)  
*A61K 9/19* (2006.01)  
*A61K 47/26* (2006.01)  
*A61K 38/17* (2006.01)  
*A61K 38/16* (2006.01)  
*A61K 47/18* (2017.01)  
*A61K 47/22* (2006.01)

(52) **U.S. Cl.**  
CPC ..... *A61K 39/39591* (2013.01); *A61K 9/0019* (2013.01); *A61K 9/08* (2013.01); *A61K 9/19* (2013.01); *A61K 31/4172* (2013.01); *A61K 31/7012* (2013.01); *A61K 38/16* (2013.01); *A61K 38/179* (2013.01); *A61K 47/02* (2013.01); *A61K 47/10* (2013.01); *A61K 47/12* (2013.01); *A61K 47/183* (2013.01); *A61K 47/22* (2013.01); *A61K 47/26* (2013.01); *C07K 14/71* (2013.01); *C07K 16/22* (2013.01); *C07K 2318/20* (2013.01); *C07K 2319/30* (2013.01)(58) **Field of Classification Search**None  
See application file for complete search history.(56) **References Cited**

## U.S. PATENT DOCUMENTS

5,399,670 A 3/1995 Bhattacharya et al.  
5,763,401 A 6/1998 Nayar  
5,851,999 A 12/1998 Ulrich et al.  
6,011,003 A 1/2000 Charnock-Jones et al.  
6,100,071 A 8/2000 Davis-Smyth et al.  
6,267,958 B1 7/2001 Andya et al.  
6,270,993 B1 8/2001 Shibuya et al.  
6,472,179 B2 10/2002 Stahl et al.  
6,875,432 B2 4/2005 Liu et al.  
6,897,294 B2 5/2005 Davis-Smyth et al.  
7,001,892 B1 2/2006 Chmielewski et al.  
7,052,691 B2 5/2006 Sleeman et al.  
7,060,268 B2 6/2006 Andya et al.  
7,087,411 B2 8/2006 Daly et al.  
7,374,757 B2 5/2008 Papadopoulos et al.  
2003/0092606 A1 5/2003 L'Italien et al.  
2003/0113316 A1 6/2003 Kaisheva et al.

(Continued)

## FOREIGN PATENT DOCUMENTS

WO WO9300807 A1 1/1993  
WO WO9913909 A1 3/1999

(Continued)

## OTHER PUBLICATIONS

Carpenter, J.F. (1997) Rational Design of Stable Lyophilized . . . , Pharm. Res. 14(8): 969-975.  
Wang, W. (1999) Instability, stabilization, and formulation of liquid protein . . . , Int'l J. Pharmaceutics 185(2): 129-188.  
Webb et al. (2002) A new mechanism for decreasing aggregation . . . , J. Pharm. Sci 93(10): 2609-2623.  
Daugherty, et al. (2006) Formulation and delivery issues for monoclonal . . . , Adv. Drug Delivery Rev. 58:668-706.  
Fraser et al. (2004) Single injections of Vascular Trap . . . , J.Clin. Endocrin. & Metabol. 90(2):1114-1122.

(Continued)

Primary Examiner — Elly-Gerald Stoica

(74) Attorney, Agent, or Firm — Kutak Rock LLP; Joseph E. Zahner

(57) **ABSTRACT**

Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.